Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Hepion Pharmaceuticals Inc (HEPA)

Hepion Pharmaceuticals Inc (HEPA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,236
  • Shares Outstanding, K 3,454
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,450 K
  • 60-Month Beta 1.66
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.66
  • Number of Estimates 2
  • High Estimate -0.57
  • Low Estimate -0.74
  • Prior Year -0.17
  • Growth Rate Est. (year over year) -288.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.01 +2.59%
on 01/06/20
5.95 -13.61%
on 12/26/19
-0.56 (-9.82%)
since 12/24/19
3-Month
2.40 +114.17%
on 11/19/19
8.35 -38.44%
on 11/27/19
+1.57 (+43.98%)
since 10/24/19
52-Week
2.00 +156.99%
on 08/15/19
25.20 -79.60%
on 03/01/19
-17.61 (-77.41%)
since 01/24/19

Most Recent Stories

More News
Hepion Pharmaceuticals Presents Update on CRV431 Nonclinical Studies at NASH-TAG 2020 Conference

EDISON, NJ / ACCESSWIRE / January 8, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising...

HEPA : 5.08 (-3.79%)
Hepion Pharmaceuticals Presents Update on CRV431 Nonclinical Studies at NASH-TAG 2020 Conference

EDISON, NJ / ACCESSWIRE / January 8, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising...

HEPA : 5.08 (-3.79%)
Hepion Pharmaceuticals Announces Publication in Expert Opinion on Investigational Drugs

EDISON, NJ / ACCESSWIRE / January 6, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising...

HEPA : 5.08 (-3.79%)
Zacks.com featured highlights include: JBGS, NWBI, THG, HEPA and HSII

Zacks.com featured highlights include: JBGS, NWBI, THG, HEPA and HSII

NWBI : 16.18 (-0.86%)
THG : 137.62 (+0.10%)
HSII : 30.87 (-1.12%)
JBGS : 40.98 (+0.15%)
HEPA : 5.08 (-3.79%)
5 Stocks in Focus as Analysts Initiate Coverage

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

NWBI : 16.18 (-0.86%)
THG : 137.62 (+0.10%)
HSII : 30.87 (-1.12%)
JBGS : 40.98 (+0.15%)
HEPA : 5.08 (-3.79%)
Zacks.com featured highlights include: NWBI, THG, RUBI, HEPA and KOF

Zacks.com featured highlights include: NWBI, THG, RUBI, HEPA and KOF

RUBI : 9.41 (-1.57%)
KOF : 62.97 (+0.27%)
NWBI : 16.18 (-0.86%)
THG : 137.62 (+0.10%)
HEPA : 5.08 (-3.79%)
Buy These 5 Stocks as New Analysts Initiate Coverage

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

RUBI : 9.41 (-1.57%)
KOF : 62.97 (+0.27%)
NWBI : 16.18 (-0.86%)
THG : 137.62 (+0.10%)
HEPA : 5.08 (-3.79%)
Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431

EDISON, NJ / ACCESSWIRE / December 10, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease...

HEPA : 5.08 (-3.79%)
Hepion Pharmaceuticals to Present Clinical and Scientific Updates at HEP DART 2019

EDISON, NJ / ACCESSWIRE / December 9, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising...

HEPA : 5.08 (-3.79%)
Hepion Pharmaceuticals Announces Canadian Research Team's Academic Appointments

University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences Appoints Hepion's Drs. Foster, Mayo, Ure and Trepanier as Adjunct Professors

HEPA : 5.08 (-3.79%)
AUPH : 18.63 (-2.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade HEPA with:

Business Summary

Hepion Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis and chronic hepatitis virus infection. The Company's lead drug candidate CRV431, reduces liver fibrosis and hepatocellular...

See More

Key Turning Points

2nd Resistance Point 5.49
1st Resistance Point 5.38
Last Price 5.08
1st Support Level 5.17
2nd Support Level 5.06

See More

52-Week High 25.20
Fibonacci 61.8% 16.34
Fibonacci 50% 13.60
Fibonacci 38.2% 10.86
Last Price 5.08
52-Week Low 2.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar